{"disease":{"id":"locally-advanced-or-metastatic-her2-positive-breast-cancer","name":"locally advanced or metastatic her2 positive breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06846437","title":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":228,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}